Literature DB >> 12081782

Antisense Bcl2 oligonucleotide in cisplatin-resistant bladder cancer cell lines.

J H Hong1, E Lee, J Hong, Y J Shin, H Ahn.   

Abstract

OBJECTIVE: To determine the change of expression of Bcl2 in cisplatin-resistant bladder cancer cell lines and the reversibility of chemoresistance to cisplatin with antisense oligonucleotide against Bcl2, as higher expression of Bcl2 is associated with drug resistance in many different cancer cell lines.
MATERIALS AND METHODS: In the cisplatin-resistant bladder tumour cell lines T24R1 and T24R2, the expression of Bcl2 was determined by reverse transcription-polymerase chain reaction and Western blot assay, and antisense oligonucleotide targeting of the Bcl2 coding sequence was administered with lipofectin.
RESULTS: The expression of Bcl2 mRNA and protein was greater in T24R1 and T24R2 cells than in the parent T24 cells. Short-term exposure to cisplatin up-regulated Bcl2 mRNA and protein expression in parent T24 cells. Treatment with antisense oligonucleotide down-regulated Bcl2 protein expression and significantly enhanced the cytotoxicity of cisplatin.
CONCLUSIONS: Up-regulation of Bcl2 protein expression might be one of the mechanisms of cisplatin resistance in bladder cancer cells, and antisense Bcl2 oligonucleotide may be helpful in chemotherapy for bladder cancer by reversing cisplatin resistance.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12081782     DOI: 10.1046/j.1464-410x.2002.02799.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  6 in total

1.  Silencing long non-coding RNA NEAT1 enhances the suppression of cell growth, invasion, and apoptosis of bladder cancer cells under cisplatin chemotherapy.

Authors:  Wenchao Zhao; Wenqi Li; Xin Jin; Tianli Niu; Yuanfei Cao; Peng Zhou; Minghua Zheng
Journal:  Int J Clin Exp Pathol       Date:  2019-02-01

Review 2.  State-of-the-art management of metastatic disease at initial presentation or recurrence.

Authors:  Fabio Calabrò; Cora N Sternberg
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

3.  In vivo evaluation of intravesical paclitaxel and combined bcl-xL antisense oligodeoxynucleotide treatment for orthotopic urothelial carcinoma.

Authors:  Christian Bolenz; Christel Weiss; Melanie Wenzel; Ute Gabriel; Annette Steidler; Andreas Becker; Edwin Herrmann; Lutz Trojan; Maurice Stephan Michel
Journal:  J Cancer Res Clin Oncol       Date:  2008-10-22       Impact factor: 4.553

Review 4.  Genetic determinants for chemo- and radiotherapy resistance in bladder cancer.

Authors:  Andrea Mari; David D'Andrea; Mohammad Abufaraj; Beat Foerster; Shoji Kimura; Shahrokh F Shariat
Journal:  Transl Androl Urol       Date:  2017-12

5.  Obatoclax, a BH3 Mimetic, Enhances Cisplatin-Induced Apoptosis and Decreases the Clonogenicity of Muscle Invasive Bladder Cancer Cells via Mechanisms That Involve the Inhibition of Pro-Survival Molecules as Well as Cell Cycle Regulators.

Authors:  Thomas M Steele; George C Talbott; Anhao Sam; Clifford G Tepper; Paramita M Ghosh; Ruth L Vinall
Journal:  Int J Mol Sci       Date:  2019-03-14       Impact factor: 5.923

6.  Advanced Urothelial Carcinoma: Overcoming Treatment Resistance through Novel Treatment Approaches.

Authors:  Richard M Bambury; Jonathan E Rosenberg
Journal:  Front Pharmacol       Date:  2013-02-06       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.